Ms Kim is a designee of New Enterprise Associates, which purchased approximately $2.3 million of the company's securities in the initial closing of the company's recent private placement.
Ms Kim is currently a director and CEO of TRF Pharma. Previously, Ms Kim was the CEO and president of Kosan Biosciences.
Ms Kim has received a BS in chemical engineering from Northwestern University and an MBA from the University of Chicago.
Daniel Swisher, CEO of Sunesis, said: "We are pleased to have Helen join the Sunesis board of directors. Helen brings a wealth of experience in corporate development as well as strategic marketing. We believe Helen's proven leadership, successful business development track record and commercial insights will benefit Sunesis significantly."
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index